- Previous Close
8.97 - Open
8.90 - Bid 8.81 x 200
- Ask 8.91 x 200
- Day's Range
8.61 - 9.01 - 52 Week Range
6.07 - 19.71 - Volume
408,294 - Avg. Volume
1,332,868 - Market Cap (intraday)
613.345M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-5.74 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.29
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
www.phathompharma.com452
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: PHAT
View More
Performance Overview: PHAT
Trailing total returns as of 2024-11-29, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHAT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHAT
View MoreValuation Measures
Market Cap
606.51M
Enterprise Value
448.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.17
Price/Book (mrq)
--
Enterprise Value/Revenue
17.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.67%
Return on Equity (ttm)
--
Revenue (ttm)
26.27M
Net Income Avi to Common (ttm)
-339.44M
Diluted EPS (ttm)
-5.74
Balance Sheet and Cash Flow
Total Cash (mrq)
334.68M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-179.77M